CD90 Is a Diagnostic Marker to Differentiate Between Malignant Pleural Mesothelioma and Lung Carcinoma With Immunohistochemistry

Kawamura, Kiyoko; Hiroshima, Kenzo; Suzuki, Takeo; Chai, Kuan; Yamaguchi, Naoto; Shingyoji, Masato; Yusa, Toshikazu; Tada, Yuji; Takiguchi, Yuichi; Shimada, Hideaki; Tagawa, Masatoshi

doi:10.1309/ajcpm2z4ngiipbge

Cited by 16 publications

(13 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, Kawamura et al in their study tried to differentiate between the difficult-todifferentiate cancer types epithelioid mesothelioma from lung carcinoma using CD90 cell surface expression. In their study, they showed that CD90 was expressed only in the epithelioid mesothelioma (15 cases) but not in lung adenocarcinoma (61 cases) [84]. Similarly, proteomic surfaceome analysis of Nglycosylated protein in mesothelioma and lung adenocarcinoma also found CD90 to be expressed exclusively in malignant pleural mesothelioma cell lines (MSTO-211H, H2052, H2452, H226) but not in lung adenocarcinoma cell lines (Calu-3, A549, Calu-6, SK-LU-1) suggesting a role for CD90 as a diagnostic marker for mesothelioma [85].…”

Section: Cd90 As Marker For Malignant Cancer Cellsmentioning

confidence: 97%

Multiple roles of CD90 in cancer

et al. 2016

View full text Add to dashboard Cite

THY1 (CD90) is a 25-37-kDa heavily N-glycosylated, glycophosphatidylinositol (GPI) anchored cell surface protein. It is usually expressed on thymocytes, mesenchymal stem cells, hematopoietic stem cells, natural killer cells, neurons, endothelial cells, renal glomerular mesangial cells, follicular dendritic cells, fibroblasts, and myofibroblasts. It has been found to regulate cell adhesion, migration, apoptosis, axon growth, cell-cell and cell-matrix interactions, T-cell activation, and fibrosis. Several reports have shown that CD90 has an important role in cancer in regulating cancer cell proliferation, metastasis, and angiogenesis. There are also evidences that CD90 is an important prognostic marker in many cancers. Consequently, therapies that target CD90 have great promise in treating many cancers. However, several studies also indicate a contradictory role for CD90, where it acts as a tumor suppressor. In this review, we summarize the expression, function of CD90 in different cancers and its possible use as a biomarker or a therapeutic target in cancer. The challenges and future prospects for the use of CD90 for clinical applications are also discussed in this review.

show abstract

Section: Cd90 As Marker For Malignant Cancer Cellsmentioning

confidence: 97%

Multiple roles of CD90 in cancer

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Lgr5 has been shown to be expressed in head and neck, colon and gastric tumors [74, 75]. CD90 has been detected in high grade human glioma [76, 77], as well as liver [78] and lung tumors [79, 80]; while CD117 has been used as a CSC marker in leukemia [81, 82] and gastrointestinal stromal tumor [83], as well as oral squamous cell carcinomas [84, 85] and ovarian tumors[86, 87]. CD117 has been shown to be overexpressed in hepatocellular [88] and pancreatic carcinoma[89].…”

Section: Introductionmentioning

confidence: 99%

Stemness-related markers in cancer

2017

View full text Add to dashboard Cite

Cancer stem cells (CSCs), with their self-renewal ability and multilineage differentiation potential, are a critical subpopulation of tumor cells that can drive tumor initiation, growth, and resistance to therapy. Like embryonic and adult stem cells, CSCs express markers that are not expressed in normal somatic cells and are thus thought to contribute towards a ‘stemness’ phenotype. This review summarizes the current knowledge of stemness-related markers in human cancers, with a particular focus on important transcription factors, protein surface markers and signaling pathways.

show abstract

“…However, compared to those mentioned previously (Table 1), they have generally lower sensitivity and/or specificity. Examples of emerging immunohistochemical markers, not yet included in standard panels are the Tenascin-X and CD90 [41][42][43].…”

Section: Other Mesothelioma Markersmentioning

confidence: 99%